SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS is drawing attention after a steep selloff amid no confirmed company update; traders debate whether broad biotech weakness and options-related trading drove the drop or whether the companys prolonged silence is adding pressure. The central catalyst remains the blinded Phase 3 REGAL trial, last reported at 78 of 80 required events: bulls see the slow event pace as a possible sign of longer survival, while bears question the delay, trial design, and prospects for a successful readout.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention amid a sharp selloff across semiconductor and AI-linked stocks, with traders debating whether concerns about AI spending, inflation and broader market risk point to further weakness or an oversold pullback. Bulls point to Intels foundry prospects and upcoming earnings, while bears question its valuation and warn the selling may continue.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

ESMO data on lifileucel is driving attention: traders are weighing mature frontline melanoma results and early sarcoma responses as encouraging signs, while noting the small cohorts and need for confirmation in larger trials. The sharp pullback is widely viewed in the discussion as part of broader biotech and market weakness rather than a clear company-specific reaction.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp futures rebound after Fridays selloff has dominated discussion, pushing back against widespread Black Monday crash fears. Bulls view the move as a relief rally or short squeeze, while skeptics call it a low-volume bull trap and question whether it will hold; some traders also speculate that Russia-related diesel and peace-talk headlines are helping sentiment.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp semiconductor selloff, amplified by its 3x daily leverage, amid concerns about AI spending and debt, Chinese competition, and persistent inflation. Traders are split between buying the steep dip and expecting a rebound, and warning that selling and forced liquidations may continue.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp tech- and AI-linked selloff followed by a strong futures rebound, with traders split over whether the bounce signals recovery or is a short-covering rally that could fade. Crash warnings, including Black Monday talk, are competing with optimism ahead of major tech earnings.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

A sharp selloff across neocloud and AI-infrastructure stocks, driven by worries about debt, financing costs, and whether heavy data-center spending will pay off, is weighing on Nebius. Traders are divided: bears see more downside as the sector faces a valuation reset, while bulls argue Nebius is financially stronger than some peers and the pullback is overdone.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Deltas quarterly earnings miss and reduced full-year outlook, driven by sharply higher fuel costs, are the main focus. Traders are split over whether strong travel and premium demand can offset margin pressure, with bulls pointing to pricing power and possible fuel relief while bears worry about further earnings weakness.

KraneShares Trust - KraneShares CSI China Internet ETF

KraneShares CSI China Internet ETF

KWEB is drawing attention amid continued weakness in Chinese internet stocks, with traders split between buying the oversold pullback and expecting further declines. Bulls cite support levels and Chinas AI potential, while skeptics point to prolonged underperformance versus U.S. tech, weak domestic demand, regulatory and geopolitical risks, and a lack of sustained inflows.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

A sharp AI-sector selloff and concerns about Super Micros governance and export-control risks are driving attention as the stock posts steep losses. Bulls call the decline an oversold buying opportunity and point to expected earnings and AI demand, while bears worry about compliance issues, management credibility, and a possible slowdown in AI spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vaso Stock Surges 149% in a Year: What's Behind the Rally?

VASO is gaining from higher equipment deliveries, growing deferred commissions and a sharper healthcare focus, though partner dependence and margin pressures persist.

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced that results from the landmark CONNECT randomized controlled trial have been published in The New England Journal of Medicine (NEJM), providing rigorous evidence of the significant benefits of continuous glucose...

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.

Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its third quarter 2026 financial results after market close on Thursday, October 29, 2026. Management will hold a conference call to review the company's third quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the...

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

DEXCOM, INC. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the launch of the fifth season of Dexcom U, the companys one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.This press release features multimedia. View the full...

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

Dexcom sees room to expand CGM adoption as low awareness, reimbursement hurdles and rising GLP-1 use create new opportunities in Type 2 diabetes.

Here's Why DexCom (DXCM) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today released its Dexcom State of Type 2 Report: Global Access and Attitudes to Diabetes Technology in advance of the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept...

Dexcom Promotes Jereme Sylvain to Chief Operating Officer

DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the promotion of Jereme Sylvain to the role of Chief Operating Officer (COO) in addition to his duties as Chief Financial Officer. In this expanded role, Mr. Sylvain will assume oversight of Dexcoms global...

DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.

Dexcom, Inc.. The group's principle activity is designing & developing of medical devices for continuous monitoring of glucose in people with diabetes. It has developed proprietary technology and expertise that enable it to develop two continuous glucose monitoring systems: a short-term system with a sensor that can be inserted by a patient and used continuously for three days, and a long-term system with a sensor that can be implanted by a physician in a short outpatient procedure requiring only local anesthesia, and can be used for up to one year. On 13-Feb-2009, it received approval from the FDA for its third generation continuous glucose monitoring system.

Dexcom Inc

Dexcom Stock Plunges 13% After-Hours As Q3 Margin Pressures Eclipse Record Profit — Retail Sees ‘Buy The Dip’ Setup

Equity

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

DXCM News